Bioventus Q3 revenue rises 3% but misses estimates
Overview
US medtech firm's Q3 revenue rose 3% but missed analyst expectations
Adjusted EBITDA for Q3 grew 7% to $28.4 mln, driven by higher revenue and cost management
Company continues to review potential strategic alternatives, as previously disclosed
Outlook
Bioventus updates 2026 net sales guidance to $590 mln-$595 mln, growth of about 4%-5%
Company reaffirms 2026 adjusted EPS guidance of $0.75-$0.79 per diluted share
Bioventus sees 2026 adjusted cash from operations at $84 mln-$89 mln
Result Drivers
PAIN TREATMENTS GROWTH - Revenue rose 6.2% in Pain Treatments, led by strong volume growth in hyaluronic acid therapy products, PRP system, and PNS products
DISCIPLINED COST MANAGEMENT - Adjusted EBITDA advanced due to higher revenue and disciplined cost management, partially offset by increased investments
RESTORATIVE THERAPIES DECLINE - Revenue in Restorative Therapies fell 3.4% due to lower volume for the EXOGEN Bone Stimulation System
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Sales | Miss | $142.40 mln | $149.46 mln (5 Analysts) |
Q3 Adjusted EBITDA | $28.40 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Bioventus Inc. is $18.00, about 35.1% above its October 30 closing price of $13.33
The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 15 three months ago
Reuters Recommended Reads
Nov 2 - Denmark medical devices maker Coloplast's Q4 revenue rises
Nov 2 - IDEXX Laboratories Q3 revenue beats estimates, lifts FY profit outlook
Nov 2 - IDEXX raises forecast, betting diagnostics can offset weak vet visits
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)